Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lokelma for Albuminuria in T2D with Hyperkalemia
NCT04063930Phase 4Unknown
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hyperkalemia and diabetic nephropathy (DN) comparing Lokelma with Placebo (2 arms). Primary endpoint: Urinary albumin creatinine ratio at 12 weeks. Status: unknown.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiadiabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04063930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063930.